Skip to main
LQDA

LQDA Stock Forecast & Price Target

LQDA Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 67%
Buy 22%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Liquidia Corp has demonstrated a strong financial outlook supported by an increase in sales estimates for its product YUTREPIA, now projected to reach peak sales of $1.7 billion to $2 billion, significantly higher than prior expectations. The company achieved operating profitability in the first full quarter following YUTREPIA's launch, aided by impressive patient outcomes, particularly a notable increase in 6-Minute Walk Distance (6MWD) metrics. Additionally, favorable Phase 3 data for L606, coupled with strategic advancements in patient transition to YUTREPIA from parenteral therapies, reinforces Liquidia's competitive positioning in the pulmonary hypertension market.

Bears say

Liquidia Corp faces considerable legal risks that could jeopardize its exclusivity and top-line growth from its primary product, YUTREPIA (treprostinil) inhalation powder. Ongoing lawsuits related to UTHR's patents and trade secret misappropriation may impair the company's operational freedom unless favorable judgments are received, which introduces significant downside risk for its stock. Additionally, even if Liquidia successfully appeals the '327 patent lawsuit, the potential for disruptions in sales and overall sales continuity raises concerns about the company's growth potential in the competitive pulmonary hypertension market.

LQDA has been analyzed by 9 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Liquidia Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Liquidia Technologies Inc (LQDA) Forecast

Analysts have given LQDA a Buy based on their latest research and market trends.

According to 9 analysts, LQDA has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Liquidia Technologies Inc (LQDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.